Risk of hepatocellular carcinoma after curative treatment when switching from tenofovir disoproxil fumarate or entecavir to tenofovir alafenamide: A real-world multicenter cohort study.
Hyunjae ShinSeung Up KimByeong Geun SongYoungsu ParkYunmi KoJeayeon ParkMoon Haeng HurYun Bin LeeEun Ju ChoJeong-Hoon LeeSu Jong YuJung-Hwan YoonDong Hyun SinnYun Joon KimPublished in: Hepatology research : the official journal of the Japan Society of Hepatology (2024)
TAF is as effective as TDF and ETV in preventing HCC recurrence after curative treatment.